Allergic rhinitis: therapeutic strategies update Lactococcus lactis Plasma and tranilast–roxithromycin combination

Main Article Content

Yasuhiro Horiuchi

Keywords

Allergic rhinitis, Tranilast, Roxithromycin, Lactococcus lactis Plasma

Abstract

* At present, there is no established definitive and reliable therapy for allergic rhinitis.


* Combined effects of tranilast, which inhibits mast cell degranulation, and a specific macrolide antibiotic, roxithromycin, which has T helper 2 (Th2) cell inhibitory effects through ligands and receptors, may aid significantly in managing allergic rhinitis.


* Lactococcus lactis strain Plasma (LC-Plasma) can induce plasmacytoid dendritic cells and consistent intake of LC-Plasma increases T helper 1 (Th1) responses, indicating a potential to suppress Th2 hypersensitivity conditions, such as allergic rhinitis.


* A novel treatment approach for hay fever can now be chosen based on to the severity of the disease and amount of scattered pollen.

Abstract 255 | PDF Downloads 481 HTML Downloads 0 XML Downloads 4

References

1. Yan S, Ai S, Huang L, Qiu C, Zhang F, He N, et al. Systematic review and meta-analysis of probiotics in the treatment of allergic rhinitis. Allergol Immunopathol (Madr). 2022;50:24–37. 10.15586/aei.v50i3.507

2. Horiuchi Y. Usefulness of Lactococcus lactis strain Plasma for treatment of allergic rhinitis: Four case reports. Eur J Rhinol Allergy. 2023;6:69–71. 10.5152/ejra.2023.23093

3. Meng Y, Wang C, Zhang L. Advances and novel developments in allergic rhinitis. Allergy. 2020;75:3069–76. 10.1111/all.14586

4. Horiuchi Y. Intractable prurigo nodularis: Synergistic effects of tranuilast and roxithromycin. Skinmed. 2022; 20:476–7.

5. Horiuchi Y. Seasonal facial erythema in a patient with allergic rhinitis treated using a combination of tranilast and roxithromycin. Immunopharmacol Immunotoxicol. 2023:45;508–10. 10.1080/08923973.2022.2151916